Replies to post #30307 on Amarin Corp Plc (AMRN)

[HDGabor]

P&L breakevenn at 25k weekly script with
- 164M revenue
- 65% GM (after KOWA fee)
- 26,8M OPEX (Q1 was 32,3M

Marine: Do not forget that Lovaza's label contains "ANCHOR" trial data till 2014 and was the only drug in class

[Whalatane]

Hi Nuke
Going by JL's ( corrected ) numbers we are looking at 32,000 patients who renew their scripts monthly ...based on JL's estimate of $1.50 revenue per cap , you are looking at $69 m revenue on a yearly basis .

Amrn will burn thru about $90m this year provided they can keep Pharmakon / BioPharma accepting only a % of revenue instead of the fixed qtly payment of $8m they were supposed to paying

So they have a way to go to break even , especially when you consider the payments due Biopharma.

The good news is that IMHO the tide is turning re the risk of elevated TG's and CV events ....thanks to the NEJM articles .
Consequently more MD's are likely to prescribe V , other parties may be interested in helping AMRN to complete Reduce It and chances are now better that RI will be stopped early for efficacy.

Kiwi